📰 Full Story
A long-standing women’s health condition long known as polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS) following a decade-long international consensus process.
The change, agreed by 56 professional and patient organisations with input from more than 22,000 people and announced in a Lancet consensus paper published May 12 and presented at an endocrinology congress in Prague, aims to shift clinical focus from ovarian appearance to the broader endocrine and metabolic drivers of the disorder.
PMOS affects an estimated one in eight women and is associated with irregular periods, excess hair growth, acne, infertility and higher lifelong risks of type 2 diabetes and cardiovascular disease.
Diagnostic criteria remain the same (two of three core features), and the transition to the new name will be phased in over several years through updated guidelines, medical education and disease coding.
Advocates say the new name should reduce stigma, speed diagnosis and prompt more comprehensive screening for metabolic and mental-health comorbidities; some patients warn the change could cause short-term confusion in clinical practice and public awareness.
🔗 Based On
🕰️ The Story So Far: An Evolving Timeline
Saturday, May 23, 2026 06:59 UTC
PCOS renamed PMOS to reflect metabolic causes
Monday, May 18, 2026 20:49 UTC
PCOS Renamed PMOS to Reflect Metabolic Reality

)



💬 Commentary